Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.

ABSTRACT:

Background

Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC.

Methods

191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated.

Results

Patients in the overweight co

SUBMITTER: Vithayathil M 

PROVIDER: S-EPMC10386929 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature